Radiolabelled Molecules for Brain Imaging with PET and SPECT II
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (1 June 2021) | Viewed by 10881
Special Issue Editor
Interests: radiotracer development for brain tumor imaging (glioblastoma, brain metastases); neuroimaging of the cholinergic system (nicotinic acetylcholine receptors, vesicular acetylcholine transporter); neuroimaging of second messenger systems (phosphodiesterases 2, 5, and 10); neuroimaging of neuromodulatory processes (sigma and cannabinoid receptors, adenosine signaling); blood–brain barrier transport of radiopharmaceuticals
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are in vivo molecular imaging tools which are widely used in nuclear medicine for the diagnosis and treatment follow-up of many brain diseases, including neurodegenerative diseases, movement and motor disorders, epilepsy, psychiatric syndromes, such as major depression and schizophrenia, or brain tumors, with glioblastoma multiforme as the most aggressive type of brain-derived cancers. The success of PET and SPECT imaging, as already outlined in the recently completed Volume I of this Special Issue, very much depends on the suitability of imaging probes, which are labeled with radionuclides of short half-lives. The delivery of those radiotracers to the brain and their subsequent quantification with PET and SPECT provides images of biochemical processes such as transport, metabolism, and neurotransmission on the molecular level. In addition to the diagnostic and therapeutic use as radiopharmaceuticals, in the field of nuclear medicine, they provide powerful tools for in vivo pharmacology during the process of preclinical drug development to identify new drug targets, to investigate the pathophysiology, to discover potential drug candidates, and to evaluate the pharmacokinetics and pharmacodynamics of drugs in vivo. Furthermore, they allow molecular imaging studies in various small-animal models of disease, including genetically-engineered animals.
All researchers working in this very interdisciplinary field are cordially invited to contribute original research papers or reviews to Volume II of this Special Issue related to the development and preclinical as well as clinical use of radiolabeled molecules for brain imaging.
Prof. Dr. Peter Brust
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PET
- SPECT
- Carbon-11
- Fluorine-18
- Radiolabelled iodine
- Technetium-99m
- Gallium-64
- Blood–brain barrier
- Alzheimer’s disease
- Parkinson’s disease
- Huntington’s disease
- Multiple sclerosis
- Epilepsy
- Depression
- Schizophrenia
- Brain cancer
- Glioblastoma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.